Milestones
1999
Incorporated as a “C” corporation in the Commonwealth of Virginia as Critical Care Innovations, Inc.; as of October 2008, name of Company changed to NuVue Therapeutics, Inc.
2000
Completed initial equity raise of $1.47 million from Founder and angel investors.
Negotiated and signed agreement with EcoCath for exclusive license of 16 patents for enhanced ultrasound guided visualization (“UGV”) technology.
2001
Expanded the scope of business to include cancer therapeutic markets.
Acquired 7% equity stake in the cryosurgical company, CryoFlex, Inc. of West Palm Beach, Florida.
2002
Completed product specifications and manufacturing costs for first generation“P1” disposable NuVue™ FNA needles.
Successfully demonstrated at Duke University that the Company’s patented “UGV” technologies allow for the precise placement of pacemaker leads and guide-wires using the next generation 3D ultrasound devices.
Closed Definitive Agreement with CryoFlex, Inc. to acquire, through an asset purchase, that company’s three patents and all trademarks for their cryosurgical technologies.
Closed Definitive Agreement with EchoCath, Inc. to acquire, through an asset purchase, 16 patents and
all trademarks for their core “UGV” enhanced ultrasound technology.
2003
Closed License Agreement (Worldwide) with National Aeronautics and Space Administration for an exclusive license for medical uses of 13 patents for microencapsulation of therapeutics and diagnostics.
Completed marketing evaluation of pre-production “P1” disposable NuVue™ FNA products.
2004-2005
Completed small animal experiments proving both the principles and concepts of the Company’s integrated platform technologies.
Submitted the first in a series of additional patents to cover the integrated and combined methods and devices the Company developed for its cryothermally enhanced, microencapsulated, controlled release drug and drug delivery systems.
2006
Completed extensive animal studies for proof of concept of (1) the acquisition of malignant tissues, (2) the positioning of a newly developed BrightMarkTM tissue site marker for the postoperative follow-up of cancer patients and (3) the delivery of numerous cytotoxic substrates as individualized multifunctional chemotherapeutic courses of therapy.
2007
Funded and conducted R&D project to miniaturize the Ultrasound Guided Visualization technologies, into a hand-held, single use, disposable device.
Continued research and development on the effects of cryothermal cooling of tissues in dual animal studies with human prostate and human lung tumors. Proved all principles and concepts pertaining to integration of all the company’s platform technologies and the synergistic responses to such integrated methodologies and processes.
2008
Formulated and submitted to USPTO four new patents covering all the proprietary technologies developed during 2006 and 2007. Submitted two more papers scribed and submitted to different cancer journals, after patents were submitted and pending.
2009-2010
Completed product specifications and manufacturing costs for second generation ColorMarkTM-A fine needle aspiration biopsy needles.
Completed and submitted application for 510(k) approval of ColorMarkTM-A fine needle aspiration biopsy needles (approval issued February 10, 2011).
|
|
|